Effects of panax notoginoside on the nephropathy in rats with type 1 diabetes mellitus

Qing-nian Tu; Hui Dong; Fu-er Lu

doi:10.1007/s11655-011-0825-9

Your Location：

Home >

Browse articles >

Effects of panax notoginoside on the nephropathy in rats with type 1 diabetes mellitus

OriginalPaper | Updated：2021-08-27

- Effects of panax notoginoside on the nephropathy in rats with type 1 diabetes mellitus
- Effects of panax notoginoside on the nephropathy in rats with type 1 diabetes mellitus
- 中国结合医学杂志（英文版） 2011年17卷第8期页码：612-615
- Affiliations：
  
  1. Department of Integrated Traditional Chinese and Western Medicine, Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology,Wuhan,China
  2. Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology,Wuhan,China
- Author bio：
- Funds：
- DOI：10.1007/s11655-011-0825-9
  中图分类号：
- 纸质出版日期：2011，
  
  网络出版日期：2011-8-9，
Scan for full text
Tu, Qn., Dong, H. & Lu, Fe. Effects of panax notoginoside on the nephropathy in rats with type 1 diabetes mellitus., Chin. J. Integr. Med. 17, 612 (2011). https://doi.org/10.1007/s11655-011-0825-9

Qing-nian Tu, Hui Dong, Fu-er Lu. Effects of panax notoginoside on the nephropathy in rats with type 1 diabetes mellitus[J]. Chinese Journal of Integrative Medicine, 2011,17(8):612-615.
Tu, Qn., Dong, H. & Lu, Fe. Effects of panax notoginoside on the nephropathy in rats with type 1 diabetes mellitus., Chin. J. Integr. Med. 17, 612 (2011). https://doi.org/10.1007/s11655-011-0825-9 DOI：

Qing-nian Tu, Hui Dong, Fu-er Lu. Effects of panax notoginoside on the nephropathy in rats with type 1 diabetes mellitus[J]. Chinese Journal of Integrative Medicine, 2011,17(8):612-615. DOI： 10.1007/s11655-011-0825-9.

摘要

To explore the effects and underlying mechanisms of Panax notoginoside (PNS) on the nephropathy in rats with type 1 diabetes. A murine model of diabetic nephropathy was set up by an intravenous injection of streptozotocin (STZ). Wistar rats were randomly divided into 5 groups: the control group

the diabetic group (DM)

the group treated with low-dosage PNS (PNS-L)

the group treated with high-dosage PNS (PNS-H) and the group treated with catopril. Rats in the PNS-L and PNS-H groups were given different dosages of PNS while rats in the catopril group were given catopril through gastrogavage every day for the next four consecutive weeks. Serum creatinine (Cr) levels

endogenous creatinine clearance rate (CCr)

and 24-h urinary microalbumin (UAlb) were examined and calculated. Meanwhile

immunohistochemistry was applied to determine the expression of vascular endothelial growth factor (VEGF) and bone morphogenetic protein-7 (BMP-7) in the kidney tissue. The levels of Cr

Ccr

and UAlb were all elevated significantly in the DM group (P<0.01). The expression of VEGF protein was increased but BMP-7 protein was decreased in the kidney tissue (P<0.01). However

the above items decreased in the PNS-L

PNS-H and catopril groups compared with the DM group (P<0.05

P<0.01). In the PNS-L

PNS-H and catopril groups

the expression of VEGF protein was decreased but BMP-7 protein was increased in the kidney tissue (P<0.05

P<0.01). PNS shows protective effects on the kidney in type 1 diabetic rats at the early stage. The protective mechanism might be closely related to its role of inhibiting the expression of VEGF protein and enhancing the expression of BMP-7 protein in the kidney.

Abstract

the diabetic group (DM)

the group treated with low-dosage PNS (PNS-L)

endogenous creatinine clearance rate (CCr)

and 24-h urinary microalbumin (UAlb) were examined and calculated. Meanwhile

immunohistochemistry was applied to determine the expression of vascular endothelial growth factor (VEGF) and bone morphogenetic protein-7 (BMP-7) in the kidney tissue. The levels of Cr

Ccr

and UAlb were all elevated significantly in the DM group (P<0.01). The expression of VEGF protein was increased but BMP-7 protein was decreased in the kidney tissue (P<0.01). However

the above items decreased in the PNS-L

PNS-H and catopril groups compared with the DM group (P<0.05

P<0.01). In the PNS-L

PNS-H and catopril groups

the expression of VEGF protein was decreased but BMP-7 protein was increased in the kidney tissue (P<0.05

关键词

type 1 diabetesdiabetic nephropathyPanax notoginoside

Keywords

type 1 diabetesdiabetic nephropathyPanax notoginoside

references

Kreisberg JI, Ayo SH. The glomerular mesangium in diabetes mellitus. Kidney Int 1993;43:109–113.

Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 1999;56:1627–1637.

Chen S, Ziyadeh FN. Vascular endothelial growth factor and diabetic nephropathy. Curr Diabete Rep 2008;8:470–476.

Zhang Y, Zhang Q. Bone morphogentic protein-7 and gremlin: new emerging therapeutic targets for diabetic nephropathy. Biochem Biophys Res Commun 2009;383:1–3.

Gao HL, Liu FY, Xia ZL. Theoretical study and application of experimental diabetic animal models. Chin J Rehabil (Chin) 2005;9:210–212.

Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B, et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 1999;48:2229–2239.

De Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001;12:993–1000.

Flyvbjerg A, Dagnaes-Hansen F, de Vriese AS, Schrijvers. BF, Tilton RG, Rasch R. Amelioration of long term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 2002;51:3090–3094.

Wang S, Chen Q, Simon TC, Strebeck F, Chaudhary L, Morrissey J, et al. Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy. Kidney Int 2003;63:2037–2049.

Wang S, de Caestecker M, Kopp J, Mitu G, Lapage J, Hirschberg R. Renal bone morphogenetic protein-7 protects against diabetic nephropathy. J Am Soc Nephrol 2006;17:2504–2512.

Dong XL, Niu SY, Xu HB, Han MY. Effects of hyperbaric oxygenation associated with Panax notoginseng saponins therapy on hemorrhology indexes in patients with ischemic cerebrovascular disease. Chin J Rehabil (Chin) 2005;9:6–7.

Guo M, Liu HY, Chen XW. The mechanisms of progression of renal interstitial fibrosis and the therapeutic effects of Panax notoginoside. Chin J Integr Tradit West Nephrol (Chin) 2007;8:175–178.

FULL TEXT LINK

More>

浏览量

797

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Total triterpene acids, isolated from Corni Fructus, ameliorate progression of renal damage in streptozotocin-induced diabetic rats

Study on the relationship between chinese medicine constitutive susceptibility and diversity of syndrome in diabetic nephropathy

Regulation of C-type natriuretic peptides and natriuretic peptide receptor-B expression in diabetic rats renal treated by Tongluo Recipe (通络方)

Association of Chinese medicine constitution susceptibility to diabetic nephropathy and transforming growth factor-β1 (T869C) gene polymorphism

Chinese Medicine for Treating Diabetic Nephropathy